• ColoSTAT® commercialisation launched, generating revenue for the first time
• NHS England partnership validates Rhythm's science on the global stage
• Next generation geneType™ test delivered ahead of schedule
• Harvard Medical School validates geneType™ ovarian cancer risk model

Rhythm Biosciences has focused on developing blood-based diagnostic tests for early cancer detection. During the Q2 FY26 period, the company commenced commercialisation activities for ColoSTAT® following the completion of required accreditation and validation processes, making it ready for Australian clinicians to help patients and generate revenue. Key achievements include the successful transition of the geneType™ laboratory to the ISO 15189:2022 standard, the initiation of ColoSTAT® commercialisation, and the announcement of a partnership with NHS England to evaluate the ColoSTAT® test. The company also made progress with its geneType™ platform, developing a network of strategic commercial partnerships to scale global sales, completing the development of an enhanced colorectal cancer risk assessment test, and publishing a peer-reviewed validation of the geneType™ ovarian cancer risk model in the prestigious Harvard Nurses' Health Study. Rhythm also strengthened its balance sheet, receiving a $1.571 million R&D tax incentive and fully repaying a $1 million loan. The company has transitioned from a development company to a commercial enterprise, with a clear focus on expanding commercial traction, leveraging strategic partnerships, and demonstrating the revenue potential of its platforms.

Rhythm Biosciences expects to see stronger geneType™ sales growth in Q3 FY26 as it executes on its strategic partnerships.

Rhythm Biosciences is excited about the momentum building in its business and is focused on expanding commercial traction, leveraging strategic partnerships, and demonstrating the revenue potential of its ColoSTAT® and geneType™ platforms.